Stryker Corporation $SYK Stock Position Reduced by Bank of New York Mellon Corp

Key Points

• Bank of New York Mellon reduced its Stryker stake by 10.2% in the second quarter, selling 403,885 shares and retaining 3.55 million shares worth approximately $1.12 billion. Institutional investors and hedge funds own 77.09% of SYK.
• Stryker reported quarterly revenue of $6.59 billion and adjusted earnings of $3.69 per share, beating analyst expectations, while revenue increased 9.4% year over year. The company guided for fiscal 2026 EPS of $14.95–$15.10.
• The stock recently traded at $327.97, down 3.5%, while analysts maintain a consensus “Moderate Buy” rating with a $386.28 average price target. Stryker also declared a quarterly dividend of $0.88 per share, equating to a 1.1% annual yield.

Bank of New York Mellon Corp decreased its stake in Stryker Corporation (NYSE:SYK - Free Report) by 10.2% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,548,516 shares of the medical technology company's stock after selling 403,885 shares during the quarter. Bank of New York Mellon Corp owned approximately 0.93% of Stryker worth $1,117,215,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Concentrum Wealth Management lifted its holdings in shares of Stryker by 4.9% during the 2nd quarter. Concentrum Wealth Management now owns 857 shares of the medical technology company's stock valued at $270,000 after buying an additional 40 shares during the last quarter. Kelleher Financial Advisors raised its position in Stryker by 208.9% during the second quarter. Kelleher Financial Advisors now owns 3,960 shares of the medical technology company's stock valued at $1,247,000 after acquiring an additional 2,678 shares in the last quarter. Russell Investments Group Ltd. raised its position in Stryker by 54.2% during the second quarter. Russell Investments Group Ltd. now owns 420,962 shares of the medical technology company's stock valued at $133,576,000 after acquiring an additional 147,977 shares in the last quarter. Avalon Trust Co lifted its stake in Stryker by 0.5% in the second quarter. Avalon Trust Co now owns 60,840 shares of the medical technology company's stock valued at $19,155,000 after acquiring an additional 300 shares during the last quarter. Finally, Clearstead Trust LLC grew its position in Stryker by 1.0% in the second quarter. Clearstead Trust LLC now owns 9,286 shares of the medical technology company's stock worth $2,924,000 after acquiring an additional 96 shares in the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Trading Down 3.5%

Shares of SYK stock opened at $327.97 on Friday. The firm has a market capitalization of $125.80 billion, a P/E ratio of 33.99, a price-to-earnings-growth ratio of 2.17 and a beta of 0.76. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $396.86. The firm's fifty day simple moving average is $326.64 and its 200 day simple moving average is $332.66. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The company had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. During the same quarter in the previous year, the firm posted $3.13 EPS. The business's revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, sell-side analysts predict that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a $0.88 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker's payout ratio is currently 36.48%.

Insider Transactions at Stryker

In related news, insider Debra King sold 826 shares of the business's stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the completion of the transaction, the insider owned 6,210 shares in the company, valued at $2,088,423. The trade was a 11.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Ronda E. Stryker sold 310,000 shares of the company's stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the transaction, the director directly owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. This represents a 13.87% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 665,370 shares of company stock worth $216,238,501. Corporate insiders own 4.60% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on SYK. Truist Financial raised their price target on shares of Stryker from $330.00 to $340.00 and gave the company a "hold" rating in a report on Friday, July 31st. BMO Capital Markets assumed coverage on shares of Stryker in a report on Wednesday, July 8th. They issued an "outperform" rating and a $369.00 price objective for the company. Needham & Company LLC cut their target price on Stryker from $454.00 to $418.00 and set a "buy" rating on the stock in a report on Friday, May 1st. Raymond James Financial set a $370.00 price target on Stryker in a research report on Friday, July 31st. Finally, Argus set a $370.00 price objective on Stryker in a report on Thursday, July 9th. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $386.28.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source